• Spinraza (nusinersen)

  SMA Study Looks at AVXS-101 vs. Spinraza

  Posted by sma-news-today-moderator on September 7, 2018 at 12:05 pm

  The Institute for Clinical and Economic Review (ICER) has shared the details of its future analysis comparing the clinical benefits and long-term cost-effectiveness of approved Spinraza (nusinersen) and investigational therapy AVXS-101 for people with spinal muscular atrophy (SMA).

  Read more about the study here.

  What are your thoughts on this news?

  sma-news-today-moderator replied 5 years, 8 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply